PRNewsWire
23 Jun 2026, 09:40 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging channel stuffing, undisclosed related party transactions, and inadequate internal controls. — Allegations of revenue inflation and fraud typically lead to severe valuation resets and loss of investor trust.
-0.80Culper Research claimed ADMA's reported 20% growth in 2025 was actually a 3% decline when accounting for payment term extensions. — A shift from high growth to contraction fundamentally alters the company's growth narrative and DCF valuation.
-0.70Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral following the short-seller report and the company's response. — Analyst downgrades reduce institutional buy-side support and signal a shift in professional sentiment.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and misleading statements, following a significant stock price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
